Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Ph ...

Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering ...

Dr. Matushansky’s appointment comes at a critical time as Immuneering plans to present updated data from the Phase 2a trial of IMM-1-104 in the second quarter of 2025. The trial is part of the ...

Dr. Matushansky, an experienced oncologist and drug development expert, will lead the clinical strategies for Immuneering’s cancer drug programs, including the ongoing Phase 2a trial of IMM-1-104, the ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced ...

The appointment comes as Immuneering is planning to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in the second quarter. Matushansky will oversee clinical activities ...

Cambridge, USA-based clinical-stage oncology company Immuneering (Nasdaq: IMRX) announced the appointment of Dr Igor ...